Kenichi Yoshimura

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda et al. · Gut · 2019 · 723 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration

Rebecka L. Meyers, Rudolf Maibach, Eiso Hiyama et al. · The Lancet Oncology · 2016 · 441 citations

Medicine, Oncology, Pediatrics +16

A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer

Masashi Kanai, Kenichi Yoshimura, Masanori Asada et al. · Cancer Chemotherapy and Pharmacology · 2010 · 398 citations · Full text

Medicine, Oncology, Pharmacology +10

Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial

Kenjiro Kimura, Tatsuo Hosoya, Shunya Uchida et al. · American Journal of Kidney Diseases · 2018 · 384 citations · Full text

Medicine, Nephrology, Pharmacotherapy +17

Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial

Masatoshi Kudo, Sadahisa Ogasawara, Shuntaro Obi et al. · ˜The œLancet. Gastroenterology & hepatology · 2018 · 309 citations · Full text

Medicine, Oncology, Pharmacology +15